Novavax (NVAX) Free Cash Flow (2010 - 2026)

Novavax's Free Cash Flow history runs 17 years deep, the most recent figure standing at -$33.7 million for Q1 2026.

• On a quarterly basis, Free Cash Flow rose 82.0% year-over-year to -$33.7 million in Q1 2026; TTM through Mar 2026 was -$96.8 million, a 49.25% increase from a year earlier, with the FY2025 full-year figure at -$250.2 million, down 183.26% from the prior year.
• Free Cash Flow climbed to -$33.7 million in Q1 2026 per NVAX's latest filing, from -$44.8 million in the prior quarter.
• Across five years, Free Cash Flow topped out at $314.9 million in Q2 2024 and bottomed at -$329.3 million in Q1 2023.
• The 5-year median for Free Cash Flow is -$105.3 million (2022), against an average of -$89.1 million.
• Across the five-year window, Free Cash Flow slumped 223.7% in 2022 and jumped 282.27% in 2024, its largest moves.
• Year by year, Free Cash Flow stood at -$55.7 million in 2022, then slumped by 150.84% to -$139.7 million in 2023, then dropped by 23.52% to -$172.6 million in 2024, then jumped by 74.06% to -$44.8 million in 2025, then gained by 24.82% to -$33.7 million in 2026.
• Per Business Quant, the three latest NVAX Free Cash Flow figures stand at -$33.7 million (Q1 2026), -$44.8 million (Q4 2025), and $109.1 million (Q3 2025).